The worldwide war on baby girls
By The Economist,
The Economist
| 03. 04. 2010
Xinran Xue, a Chinese writer, describes visiting a peasant family in the Yimeng area of Shandong province. The wife was giving birth. "We had scarcely sat down in the kitchen", she writes, "when we heard a moan of pain from the bedroom next door…The cries from the inner room grew louder-and abruptly stopped. There was a low sob, and then a man's gruff voice said accusingly: 'Useless thing!'
"Suddenly, I thought I heard a slight movement in the slops pail behind me," Miss Xinran remembers. "To my absolute horror, I saw a tiny foot poking out of the pail. The midwife must have dropped that tiny baby alive into the slops pail! I nearly threw myself at it, but the two policemen [who had accompanied me] held my shoulders in a firm grip. 'Don't move, you can't save it, it's too late.'
"'But that's...murder...and you're the police!' The little foot was still now. The policemen held on to me for a few more minutes. 'Doing a baby girl is not a big thing around here,' [an] older woman said comfortingly...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...